Date:	11/29/2022
Your Name:	Benjamin Maasoumy
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ None German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	s
2	Grants or contracts from any entity (if not indicated in item #1 above).	□ None Roche Diagnostics Altona Diagnostics Fujirebio	Research grant Research grant Research grant
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	AbbVie Luvos	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	AbbVie Norgine Gilead Roche MSD Falk Fujirebio	lecture
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	Gilead AbbVie	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None ■	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None ■	

			e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	Bior	None Tech	<5000€
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services		None	
13	Other financial or non-financial interests		None	
Plea	Please place an "X" next to the following statement to indicate your agreement:			
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	11/22/2022
Your Name:	Patrick INGILIZ
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	GILEAD Abbott Laboratories	NoCo, HDV Describe
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead Abbvie Eiger	Lectures Lectures lectures
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None Abbvie	Meeting and Travel
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Date:	11/23/2022
Your Name:	Dr. Spinner, Christoph D.
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present	□ None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF)	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research
		Gilead Sciences	Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None Muliptle	CDS reports grants and personal fees from AbbVie, grants, fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, grants and personal fees from MSD

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
3	Royalties or licenses	None	
4	Consulting fees	□ None	
		Muliptle	CDS reports grants and personal fees from AbbVie, grants, fees and non-financial support from Gilead Sciences, grants and personal fees from Janssen-Cilag, grants and personal fees from MSD, grants from Cepheid, personal fees from GSK, grants and personal fees from ViiV Healthcare, during the conduct of the study; fees from AstraZeneca, other from Apeiron, grants, personal fees and non-financial support from BBraun Melsungen, grants, personal fees from BioNtech, personal fees from Eli Lilly, personal fees from Formycon, personal fees from Moderna, personal fees from Molecular partners, personal fees from Novartis, grants and personal fees from Eli Lilly, personal fees from Roche, personal fees from SOB, personal fees from Pfizer outside the submitted work
5	Payment or honoraria for	□ None	
	lectures, presentations,		s. 4
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	Image: Second control of the control	
7	Support for attending	□ None	
	meetings and/or travel	Multiple	s. 4

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

11/23/2022

Date:

this item.

Grants or

3

contracts from any entity (if not indicated in item #1 above).

Royalties or

licenses

None

None

Your Name:	Christiane Cordes	
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in HCV V study	patients with acute hepatitis C: The HepNet acute
Manuscript Number (if known)	: JHEPR-D-22-00684	
content of your manuscript. "R affected by the content of the n indicate a bias. If you are in dou The author's relationships/active pidemiology of hypertension, you that medication is not mentioned."	elated" means any relation with for-profit or nanuscript. Disclosure represents a commitme obt about whether to list a relationship/activities/interests should be defined broadly. For you should declare all relationships with manuard in the manuscript.	y/interest, it is preferable that you do so.
	all entities with whom you have this nship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning	of the work
1 All support for the present	None	
	an Center for Infection Research (DZIF)	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research
article processing Gilea charges, etc.)	d Sciences	Financial funding and provision of study medication

Time frame: past 36 months

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	x None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	x None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	ViiV MSD Gilead	Advisory Board HIV Advisory Board HIV Advisory Board HIV
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	⊠ None	

9	Other financial or non-financial	⊠ None	
	interests		Experience of the control of the con
		And the second s	

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

23.M. 2022

Date:	11/23/2022
Your Name:	Hans-Jürgen Stellbrink
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	⊠ None	
		German Center for Infection Research (DZIF)	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research
	article processing charges, etc.)	Gilead Sciences	Financial funding and provision of study medication
	No time limit for this item.		
		Time frame: past 36 mont	hs
2	Grants or contracts from	□ None	
	any entity (if not	Gilead Sciences	Institution
	indicated in item	ViiV Healthcare, GlaxoSmithKline	Institution
	#1 above).	MSD Sharp & Dohme; Heidelberg Immunotherapeutics	Institution
3	Royalties or licenses	⊠ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	□ None	
		Gilead Sciences	To me
		ViiV Healthcare	To me
		MSD Sharp & Dohme	To me
5	Payment or honoraria for	□ None	
	lectures,	Gilead Sciences	To me
	presentations,	ViiV Healthcare	To me
	speakers	Janssen-Cilag	To me
	bureaus,	MSD Sharp & Dohme	To me
	manuscript writing or educational events		
6	Payment for expert testimony	□ None	
		Gilead Sciences	To me
			- Andrews - Andr
7	Support for attending meetings and/or travel	None None None	
		Gilead Sciences	To me
8	Patents planned, issued or	⊠ None	
	pending		
9	Participation on a Data Safety	□ None	
	Monitoring	Gilead Sciences	To me
	Board or	ViiV Healthcare	To me
	Advisory Board	MSD Sharp & Dohme	To me
10	Leadership or fiduciary role in	None	
	other board,	Member of the EACS guideline writing committee	
	society,	Chairman of the German AIDS Society	
	committee or	Member of the Federal Off Label Treatment	
	advocacy group,	Committee	
	paid or unpaid		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	Gilead Sciences	
13	Other financial or non-financial interests	None None	
Ple		at to the following statement to indicate your agreement to answered every question and have not altered the wo	

Date:	11/28/2022
Your Name:	Julian Schulze zur Wiesch
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead, Abbvie	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	⊠ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	-	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	11/26/2022
Your Name:	Stephan M. Schneeweiss
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	11/30/2022
Your Name:	Katja Deterding
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past 36 months None Gilead research grant	Financial research support
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead	Lecture fees
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Gilead advisory board	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	11/22/2022
Your Name:	Tobias Müller
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	11/22/2022
Your Name:	Julia Kahlhöfer
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	•	t to the following statement to indicate your agreeme answered every question and have not altered the wo	

Date:	11/26/2022
Your Name:	Petra Dörge
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning o	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	⊠ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea	ise place an "X" nex	t to the following statement to indicate your agreeme	ent:
\boxtimes	I certify that I have	answered every question and have not altered the wo	ording of any of the questions on this form.

Date:	11/23/2022
Your Name:	Maria von Karpowitz
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning of	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	□ None German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	5
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None None	
7	Support for attending meetings and/or travel	None ■	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Plea ⊠	•	e following statement to indicate your agreeme	

Date	e:	11/30/2022	
You	r Name:	Michael Manns	
Maı	nuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in p	atients with acute hepatitis C: The HepNet acute
Mai	nuscript Number (if knov	wn): JHEPR-D-22-00684	
con affe	tent of your manuscript. cted by the content of th	cy, we ask you to disclose all relationships/activities "Related" means any relation with for-profit or not manuscript. Disclosure represents a commitme doubt about whether to list a relationship/activity	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily
epic		ctivities/interests should be defined broadly. For early, you should declare all relationships with manufioned in the manuscript.	
	em #1 below, report all s ne for disclosure is the pa	support for the work reported in this manuscript wast 36 months.	rithout time limit. For all other items, the time
	N		
		ame all entities with whom you have this lationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		•	made to you or to your institution)
1	All support for the	lationship or indicate none (add rows as needed)	made to you or to your institution)
1	All support for the present	lationship or indicate none (add rows as needed) Time frame: Since the initial planning	made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	Iationship or indicate none (add rows as needed) Time frame: Since the initial planning None	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	Time frame: Since the initial planning None German Center for Infection Research (DZIF)	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initial planning None German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initial planning None German Center for Infection Research (DZIF)	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.

1 12/13/2021 ICMJE Disclosure Form

Royalties or

licenses

⊠ None

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Assembly Bio, Bristol Myers Squibb, Falk Pharma, Gilead, Merck (MSD)	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Abbvie, Bristol Myers Squibb, Falk Pharma, Gilead, Merck (MSD)	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Abbvie, Bristol Myers Squibb, Falk Pharma, Gilead, Merck (MSD)	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Falk Pharma, Gilead, Merck (MSD)	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	Merck (MSD)	Principal Investigator (Study)
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Hannover, 30 Nov 2022

Prof. Dr. Michael P. Manns

ICIVISE DISCLOSURE I ORIVI					
Dat	te:	11/23/2022	11/23/2022		
You	ır Name:	Heiner Wedemeyer			
Ma	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study				
Ma	Manuscript Number (if known): JHEPR-D-22-00684				
cor affe ind The epi tha	In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.				
	Name all entities with whom you have this relationship or indicate none (add rows as needed) Specifications/Comments (e.g., if payments were made to you or to your institution)				
		Time frame: Since the initial planning o	of the work		
1	All support for the present manuscript (e.g.,	□ None German Center for Infection Research (DZIF)	Financial funding by a grant of the DZIF, TTU		
	funding provision	Octiman center for infection nesearch (DZIF)	Thiancial fulluling by a grafit of the DZIF, 110		

funding, provision Hepatitis, to the HepNet Study-House of the of study materials, German Liver Foundation (DLS); DZIF is funded by medical writing, the Federal Ministry of Education and Research article processing **Gilead Sciences** Financial funding and provision of study charges, etc.) medicationNo time limit for Click the tab key to add additional rows this item. Time frame: past 36 months 2 Grants or None contracts from any entity (if not Abbvie, Biotest, Gilead, Merck/MSD, Roche indicated in item #1 above). Royalties or **⋈** None licenses

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Abbvie, Aligos, Altimmune, Biotest, BMS, BTG, Dicerna, Enanta, Gilead, Janssen, Merck/MSD, MYR GmbH, Roche, Vir Biotechnology	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Abbvie, Biotest, Gilead, Merck/MSD	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	Abbvie, Altimmune, BMS, Gilead, Janssen, Merck/MSD, MYR GmbH, Novartis, Vir Biotechnology	Clinical Trial Principal Investigator
Plea	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.		

Hannover, 23 November 2022 Prof. Dr. Heiner Wedemeyer

Date:	11/28/2022
Your Name:	Markus Cornberg
Manuscript Title:	Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV V study
Manuscript Number (if known):	JHEPR-D-22-00684

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	Time frame: Since the initial planning of the work		of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	German Center for Infection Research (DZIF) Gilead Sciences	Financial funding by a grant of the DZIF, TTU Hepatitis, to the HepNet Study-House of the German Liver Foundation (DLS); DZIF is funded by the Federal Ministry of Education and Research Financial funding and provision of study medication Click the tab key to add additional rows.
		Time frame: past 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Gilead Sciences Abbvie, MSD Sharp&Dohme, AiCuris, GSK, Roche Novartis, SOBI	Payments were made to me
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Gilead Sciences, Abbvie, MSD Sharp&Dohme Falk	Payments were made to me
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Abbvie	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	
Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			